NRx Pharmaceuticals (NRXP) said the Independent Data Safety Monitoring Board found no new safety concerns in the ACTIV-3b Critical Care phase 3 study, after reviewing 231 patients, and recommended continued enrollment. ACTIV-3b is a randomized, placebo-controlled trial testing ZYESAMI and remdesivir - alone and in combination - in hospitalized patients with acute respiratory failure due to COVID-19 who require high-flow supplemental oxygen.
"With this second independent safety analysis in the ACTIV-3b trial, the safety database on ZYESAMI has grown to more than 500 patients. So far, there have been no reports of unexpected, drug-related serious adverse events," said Jonathan Javitt, CEO of NRx.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.